Modafinil: expanded options for the treatment of excessive sleepiness
نویسنده
چکیده
10.2217/14750708.2.2.191 © 2 part of Modafinil is an oral wake-promoting agent, initially approved in December 1998 for the treatment of excessive sleepiness associated with narcolepsy. Based on the results of additional randomized, placebo-controlled studies, the indication for modafinil was expanded in January 2004 to include excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder. Modafinil represents a safer alternative to CNS stimulants for the treatment of excessive sleepiness and it has become the most widely prescribed agent for excessive sleepiness associated with narcolepsy over the past 5 years. This article summarizes the key studies on modafinil, outlining the unique pharmacologic profile, efficacy and safety.
منابع مشابه
Efficacy of modafinil on excessive daytime sleepiness in Prader-Willi syndrome.
Excessive daytime sleepiness is a frequent and a highly disruptive symptom to the daily routine of children with Prader-Willi Syndrome (PWS) and their families. The objective of the study was to evaluate the efficacy of modafinil, a central stimulant, on excessive daytime sleepiness in children and adolescents with PWS. The efficacy of modafinil was evaluated in this open label pilot study comp...
متن کاملModafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
OBJECTIVES To assess the therapeutic efficacy of modafinil in the treatment of increased daytime sleepiness in patients with Parkinson's disease (PD). DESIGN Double-blind, randomized, placebo-controlled crossover study with two 2-week treatment blocks, separated by a 2-week washout phase. SETTING Tertiary Parkinson's disease care center and sleep laboratory at university hospital neurology ...
متن کاملModafinil ameliorates excessive daytime sleepiness after traumatic brain injury.
BACKGROUND Excessive daytime sleepiness (EDS) and fatigue are common symptoms after traumatic brain injury (TBI), but there is no specific treatment for affected patients. With this pilot study, we aimed at studying the effect of daily modafinil on posttraumatic EDS and fatigue. METHODS We conducted a prospective, double-blind, randomized, placebo-controlled pilot study in 20 patients with TB...
متن کاملPharmacotherapy for excessive daytime sleepiness.
Excessive daytime sleepiness (EDS) has recognized detrimental consequences such as road traffic accidents, impaired psychological functioning and reduced work performance. EDS can result from multiple causes such as sleep deprivation, sleep fragmentation, neurological, psychiatric and circadian rhythm disorders. Treating the underlying cause of EDS remains the mainstay of therapy but in those w...
متن کاملArmodafinil in the treatment of excessive sleepiness
IMPORTANCE OF THE FIELD Excessive sleepiness causes impaired quality of life and increases the risk of poor health and accidents. Armodafinil is a wake-promoting agent approved in 2007 by the US Food and Drug Administration for the treatment of excessive sleepiness arising from narcolepsy, obstructive sleep apnea (OSA; even after optimal treatment for the underlying obstruction) and shift-work ...
متن کامل